1. A review of current treatment strategies for infective endocarditis
- Author
-
Ines Lakbar, David Luque Paz, Pierre Tattevin, CHU Pontchaillou [Rennes], CHU Toulouse [Toulouse], ARN régulateurs bactériens et médecine (BRM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), This paper was not funded., Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
0301 basic medicine ,Microbiology (medical) ,Oral treatment ,medicine.medical_specialty ,Prosthesis-Related Infections ,Time Factors ,empirical treatment ,medicine.drug_class ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Antibiotics ,Heart Valve Diseases ,review ,Microbiology ,antibiotics ,03 medical and health sciences ,0302 clinical medicine ,enterococci ,Virology ,medicine ,Endocarditis ,Animals ,Humans ,030212 general & internal medicine ,Intensive care medicine ,staphylococci ,treatment ,business.industry ,HACEK ,oral treatment ,Endocarditis, Bacterial ,medicine.disease ,3. Good health ,Anti-Bacterial Agents ,Empirical treatment ,Infectious Diseases ,streptococci ,Infective endocarditis ,Heart Valve Prosthesis ,Treatment strategy ,business - Abstract
International audience; Introduction Infective endocarditis is one of the most difficult-to-treat infectious diseases. Areas covered We restricted this review to the anti-infective treatment of the main bacteria responsible for infective endocarditis, i.e. staphylococci, streptococci, enterococci, and Gram-negative bacilli, including HACEK. Specific topics of major interest in treatment strategy are covered as well, including empirical treatment, oral switch, and treatment duration. We searched in the MEDLINE database to identify relevant studies, trials, reviews, or meta-analyses until May 2020. Expert opinion The use of aminoglycosides for the treatment of endocarditis has been dramatically reduced over the last 20 years. It should be administered once daily, and no longer than 2 weeks. For staphylococcal endocarditis, recent data reinforced the role of anti-staphylococcal penicillins, for methicillin-susceptible isolates (alternative, cefazolin), and vancomycin for methicillin-resistant isolates (alternative, daptomycin). For staphylococcal prosthetic-valve endocarditis, these treatments will be reinforced by the addition of gentamicin during the first 2 weeks, and rifampin throughout the whole treatment duration, i.e. 6 weeks. The optimal duration of antibacterial treatment is 4 weeks for most native valve endocarditis, and 6 weeks for prosthetic-valve endocarditis. The oral switch is safe in patients stabilized after the initial intravenous course.
- Published
- 2021